Andrew Technologies Shares Clinical Experience of Breakthrough HydraSolve(TM) Lipoplasty System at American Society for Aesthetic Plastic Surgery 2013 –
Plastic Surgeon Christopher Godek to Discuss New Findings
IRVINE, Calif., April 10, 2013 /PRNewswire/ — Andrew Technologies is pleased to announce that they will be sharing clinical experiences from the ongoing expert release of HydraSolve(TM) Lipoplasty System www.hydrasolve.com at Booth # 433 at Javits Center in New York City during the American Society for Aesthetic Plastic Surgery 2013. Andrew Technologies will also be taking orders for the national expansion of this innovative liposuction technology that features a non-cutting, non-thrusting, target-tissue-specific method of fat removal.
Additionally, plastic surgeon Dr. Christopher Godek of The Personal Enhancement Center in Toms River, New Jersey www.personalenhancementcenter.com, who has had the most clinical experience with HydraSolve(TM) Lipoplasty System to date, will be available at the Andrew Technologies booth to share his experiences with fellow surgeons and members of the media on Saturday, April 13, 10am – 11am.
HydraSolve(TM) is a novel liposuction device based on the same patented Tissue Liquefaction Technology(TM) that was launched in 2003 by Alcon as the AquaLase(®) Liquefaction Device, a modality on the Infiniti Vision System, for precision cataract surgery. Hydrasolve(TM) combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve(TM) cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while preserving blood vessels, nerves and connective tissue integrity. HydraSolve(TM) achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes.
Dr. Christopher Godek is a board-certified plastic surgeon who served as President of the New Jersey Society of Plastic Surgeons. He has been a scientific advisor to Andrew Technologies since 2005 and was instrumental in the design and technical features of the HydraSolve(TM) Lipoplasty System. According to Godek, “From my clinical experience, I have found that HydraSolve(TM) provides faster, smoother fat extraction for the surgeon, with a quicker recovery for patients. I look forward to sharing my clinical observations with those that are interested in improving liposuction outcomes.”
Tom Albright, CEO of Andrew Technologies, says, “Over 15 million U.S. adults are considering liposuction treatment (ICOM 2011), but only 400,000 are estimated to get treated annually. From my past experience, this indicates that we have enormous potential for market expansion. We look forward to working closely with the members of ASAPS to offer the body contouring experience that our rigorous market research indicates consumers are seeking.”
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007 by Mark S. Andrew, M.D., is a medical technology company committed to improving patients’ lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures www.wfdventures.com and NJTC Venture Fund www.njtcvc.com .
SOURCE Andrew Technologies, LLC